World
Servier's $1.55 billion muscular dystrophy drug fails major test Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
Dr. Kai NakamuraChief Science CorrespondentPublished Nov 3, 2026 at 4:17 PM EST · 1 min read
Servier's $1.55 billion muscular dystrophy drug fails major test Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment. Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.